Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
This Soaring Stock Just Delivered More Good News. Time to Buy?
08:30am, Friday, 02'nd May 2025
It's hard to find a biotech company that has performed better than Summit Therapeutics (SMMT 2.86%) in the past year. The stock is up by a whopping 512%, and it's no secret why.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
04:09pm, Thursday, 01'st May 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for
Why Is Summit Therapeutics Stock Trading Higher On Monday?
01:00pm, Monday, 28'th Apr 2025
Summit Therapeutics Inc. SMMT on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indicat
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
05:05pm, Friday, 25'th Apr 2025
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTec
What's Going On With Summit Therapeutics Stock On Friday?
03:14pm, Friday, 25'th Apr 2025
Summit Therapeutics Inc SMMT stock is trading lower on Friday.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonesc
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
04:15pm, Thursday, 24'th Apr 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2025 financial results
Why Is Summit Therapeutics Stock Soaring On Wednesday?
03:47pm, Wednesday, 23'rd Apr 2025
Summit Therapeutics Inc.'s SMMT partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Pha
This Company's Co-CEOs Just Bought More Shares. Should You?
05:45am, Wednesday, 23'rd Apr 2025
Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
09:08am, Monday, 14'th Apr 2025
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in
3 Magnificent Stocks That Could Double or More by 2030
02:45pm, Saturday, 12'th Apr 2025
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with signif
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
04:36pm, Thursday, 10'th Apr 2025
Shares of lung cancer-focused biotech Summit Therapeutics (SMMT 10.72%) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
07:02am, Sunday, 06'th Apr 2025
Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the trailing-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 04'th Apr 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
